Abstract
The treatment of choice for the failure to restore neurogenic bladder dysfunction, managed with clean intermittent catheterization program with incontinence, is anticholinergic medication. The goal is to increase bladder capacity, and decrease intravesical pressure in order to maintain continence between catheterizations. The most commonly used anticholinergic medication in the United States is Oxybutynin. Previous clinical studies have shown that 61% of the patients on oral Oxybutynin report adverse systemic side effects and are noncompliant in taking it. In 48% of the patients, possibly due to their noncompliance, oral Oxybutynin Hydrochloride is ineffective.1,2
In this study, 13 spinal cord injured patients with a failure to restore bladder dysfunction were treated with intravesical Oxybutynin. Nine patients improved on the regimen while one patient underwent surgical bladder augmentation. Postoperatively, this patient continued to be incontinent between catheterizations. Reinstitution of intravesical Oxybutynin stabilized the patient's bladder with clean intermittent catheterization without further intervention.
After 3 months post instillation in the urodynamic studies, the mean bladder capacity increased, the mean volume at first contraction increased and the leak point pressure decreased. The decrease in leak point pressure was statistically significant. Leak point pressure is one of the most important parameters we monitor to preserve upper urinary tract function. We recommend the trial of intravesical Oxybutynin for patients who fit the criteria of the protocol prior to surgical bladder augmentation.
Similar content being viewed by others
Article PDF
References
Thompson I M, Lauvetz R . Oxybutynin in bladder spasm, neurogenic bladder and enuresis. Urology 1976; 8: 452–454.
Holmes D M, Montz F J, Stanton S L . Oxybutynin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial. Br J Ob Gyn 1989; 96: 607–612.
Thuroff J W, Bunke B et al. Randomized, double-blind, multi-center trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propanthe line versus placebo. J Urol 1991; 145: 813–817.
Brooks M E, Braf Z F . Oxybutynin Chloride (Ditropan)-clinical uses and limitations. Paraplegia 1980; 18: 64–68.
Gajewki J B, Awad S A . Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986; 135: 966–968.
Moisey C U, Stephenson T P, Brendler C B . The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980; 52: 472–475.
Gillenwater J Y . Adult and pediatric urology. 2nd ed. St Louis: Mosby Year Book. 1991.
Greenfield S P, Fera M . The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 1991; 146: 532–534.
Massad C A, Kogan B A, Trigo-Rocha F E . The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992; 148: 595–597.
Mizunga M et al. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neurogenic bladder. Poster presentation, Kobe, Japan 1994, Annual conference of the International Paraplegia Society.
Brendler C B, Radebaugh L C, Mohler J L . Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141: 1350–1351.
Kasabian N G, Vlachiotis J D et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 1994; 151: 944–945.
Weese D L, Roskamp D A, Leach G E, Zimmern P E . Intravesical oxybutynin chloride: experience with 42 patients. Urol 1993; 41: 527–530.
Mohler J L . Relaxation of intestinal bladders by intravesical oxybutynin chloride. Neuro Urol 1990; 9: 179–187.
Mattiasson A, Ikstrom B, Andersen K B . Effects of intravesical instillation of verapamil in patients with detrusor hyperactivity. Neuro Urol Urodyn 1987; 6: 253–254.
Brendler C B, Radebaugh L C, Molher J L . Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989; 141: 1350–1352.
Madersbacher H, Jilg G . Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia 1991; 29: 84–90.
Dykstra D D, Sidi A A et al. Effects of botulinum a toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919–922.
Fall M, Ohlsson B L, Carlsson C A . The neurogenic overactive bladder, classification based on urodynamics. Br J of Urol 1989; 64: 368–373.
Perkash I . Long-term urologic management of the patient with spinal cord injury. Urol Clinics of N Amer, 1993; 20-3: 423–434.
de Groat W, Booth A M . Physiology of the urinary bladder and urethra. Annals of I M 1980: 92(Part 2): 312–315.
de Groat W, Kawatani M . Neurol Control of the urinary bladder: possible relationship between peptidergic inhibitory mechanisms and detrusor instability. Neuro and Urol 1985; 4: 285–300.
Bonney W, Robinson R, Theobald R J . Topical effect of intravesical oxybutynin. J of Urol 1993; 150: 1522–1525.
Juma S, Mostavfavi M, Joseph A . Sphincterotomy: long term complications and warning signs. Neurology and Urodynamics 1995; 14: 33–41.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Szollar, S., Lee, S. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 34, 284–287 (1996). https://doi.org/10.1038/sc.1996.51
Issue Date:
DOI: https://doi.org/10.1038/sc.1996.51
Keywords
This article is cited by
-
Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis
International Urology and Nephrology (2022)
-
Urological Care After Spinal Cord Injury
Current Physical Medicine and Rehabilitation Reports (2022)
-
An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction
Spinal Cord (2016)
-
Oxybutynin: past, present, and future
International Urogynecology Journal (2013)
-
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
Advances in Therapy (2013)